Objective. To evaluate whether tocilizumab (TCZ) monotherapy is noninferior to treatment with TCZ plus methotrexate (MTX) for maintaining clinical responses in patients with rheumatoid arthritis (RA) in whom low disease activity is achieved with TCZ plus MTX.
Objective. To evaluate whether tocilizumab (TCZ) monotherapy is noninferior to treatment with TCZ plus methotrexate (MTX) for maintaining clinical responses in patients with rheumatoid arthritis (RA) in whom low disease activity is achieved with TCZ plus MTX.
Methods. Patients with RA who experienced an inadequate response to MTX received MTX plus TCZ 162 mg subcutaneously. At 24 weeks, patients who achieved a Disease Activity Score in 28 joints using the erythrocyte sedimentation rate (DAS28-ESR) of ≤3.2 were randomized to receive TCZ monotherapy or to continue treatment with TCZ plus MTX until week 52. The primary outcome measure was the comparison of the mean change in the DAS28-ESR from week 24 to week 40 between the TCZ monotherapy and TCZ plus MTX arms (noninferiority margin of 0.6). Secondary outcome measures included worsening of the DAS28-ESR by ≥1.2, achievement of a DAS28-ESR of <2.6 and ≤3.2, and safety and immunogenicity.
Results. Among the 718 patients enrolled, 296 were randomized at week 24 to receive TCZ monotherapy (n = 147) or TCZ plus MTX (n = 147). The mean changes in the DAS28-ESR from week 24 to week 40 were 0.46 and 0.14 in the TCZ monotherapy arm and the TCZ plus MTX arm, respectively (weighted difference between the groups, 0.318 [95% confidence interval 0.045, 0.592]); discontinuing MTX in TCZ responders was noninferior to continuing MTX. Safety events were broadly similar between the randomized treatment groups; the most common serious adverse event was infection, which occurred in 2.1% of patients in the TCZ monotherapy group and 2.2% of patients receiving TCZ plus MTX.
Conclusion. Patients with RA receiving TCZ plus MTX who achieve low disease activity can discontinue MTX without significant worsening of disease activity during the 16 weeks following MTX discontinuation.
Tocilizumab (TCZ) is a humanized monoclonal antibody against the interleukin-6 (IL-6) receptor. As evidenced by the results of an extensive clinical trial program, TCZ (as either an intravenous or a subcutaneous formulation) has proven efficacy in treating rheumatoid arthritis (RA), giant cell arteritis, systemic juvenile idiopathic arthritis, and polyarticular juvenile idiopathic arthritis (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) . Methotrexate (MTX) is frequently administered in combination with biologics for the treatment of RA. This practice is based on studies demonstrating that biologics (primarily tumor necrosis factor [TNF] inhibitors) are more effective when used in combination with MTX (11, 12) . In contrast, the efficacy of TCZ has been demonstrated to be similar in patients with RA regardless of whether TCZ is administered as monotherapy or in combination with MTX; studies of TCZ monotherapy to date have been conducted primarily with the intravenous formulation of TCZ (4, (13) (14) (15) (16) .
Previous studies that established the efficacy of TCZ monotherapy in RA patients with active disease were performed in patients in whom TCZ was initiated as monotherapy (4, (13) (14) (15) (16) . However, another clinically pertinent route to biologic monotherapy involves initiation of a biologic in combination with existing background MTX followed by discontinuation of MTX for reasons including intolerance, nonadherence, and/or reduction in the medication burden once disease control is achieved. Notably, approximately one-third of patients with RA who require biologic treatment in clinical practice receive a biologic as monotherapy (17) (18) (19) , often because of absolute or patient-perceived intolerance of MTX (20) (21) (22) . Studies examining the efficacy of TCZ monotherapy after discontinuation of concurrently administered MTX are lacking. The objective of this noninferiority study was to evaluate the efficacy of subcutaneous TCZ monotherapy compared with that of TCZ plus MTX in maintaining response in patients with RA who achieve low disease activity following treatment with TCZ plus MTX.
PATIENTS AND METHODS
Study design. COMP-ACT is a randomized, multicenter, double-blind, parallel group, 52-week study (plus 8 weeks of follow- Figure 1 . A, Study design. Open-label subcutaneous tocilizumab (TCZ-SC) was administered for the entire study duration. B, Patient disposition. q2w = every 2 weeks; MTX = methotrexate; qw = every week; DAS28-ESR = Disease Activity Score in 28 joints using the erythrocyte sedimentation rate; NI = noninferiority; DMARD = disease-modifying antiinflammatory drug; R = randomization; mono = monotherapy; OL = open-label; AE = adverse event.
up) of TCZ plus MTX and TCZ monotherapy in patients with RA who have had an inadequate response to MTX ( Figure 1A ). Starting at baseline (week 0), all patients received TCZ subcutaneously at a dosage of 162 mg weekly (for patients weighing ≥100 kg) or every 2 weeks (for patients weighing <100 kg) and continued to receive a stable pre-baseline dosage of oral MTX of ≥15 mg/week. Patients receiving subcutaneous TCZ every 2 weeks who did not achieve a Disease Activity Score in 28 joints using the erythrocyte sedimentation rate (DAS28-ESR) (23) Outcome measures. The primary efficacy end point was the comparison of the mean change in the DAS28-ESR from week 24 to week 40 between the 2 randomized groups (TCZ monotherapy versus TCZ plus MTX). Secondary end points included the proportion of patients with worsening in the DAS28-ESR of ≥1.2 between week 24 and week 40; the proportion of patients with a DAS28-ESR of <2.6 and ≤3.2 at week 40 and week 52; the proportion of patients achieving 20%, 50%, or 70% improvement according to the American College of Rheumatology criteria (ACR20, ACR50, and ACR70, respectively) (24) at weeks 40 and 52; safety, including the incidence of adverse events (AEs) and serious AEs (SAEs); and immunogenicity. For immunogenicity testing, blood samples obtained from patients were tested for anti-TCZ antibodies at baseline (week 0), every 3 months, and then 8 weeks after administration of the last TCZ dose.
Patient population. Patients age ≥18 years and weighing ≤150 kg who had moderate to severe RA (DAS28 ≥4.4) according to the 1987 revised classification criteria (25) were included. All patients had an inadequate response to MTX; up to~20% of patients could have previously received a single TNF inhibitor ≥6 months prior to screening. Patients must have been receiving MTX for ≥24 weeks, at a stable dosage of ≥15 mg/week orally for ≥6 weeks, prior to the initiation of treatment (day 1). A stable dosage of MTX of ≥10 mg/ week was acceptable in patients weighing <50 kg or with a calculated glomerular filtration rate (or creatinine clearance rate) of <60 ml/minute.
Major exclusion criteria were documented intolerance of oral MTX at a dosage of ≥15 mg/week; treatment with a non-MTX DMARD within 8 weeks of screening; previous treatment with abatacept, rituximab, tofacitinib, or anakinra; use of parenteral corticosteroids within 4 weeks prior to treatment; treatment with cell-depleting therapies, intravenous immunoglobulin, or plasmapheresis within 6 months of baseline (week 0); and previous treatment with TCZ or any IL-6 antagonist.
This study was approved by the institutional review boards and independent ethics committees of the investigational centers. All patients provided written informed consent, in accordance with the Declaration of Helsinki.
Statistical analysis. Primary end point analysis was performed in randomized patients who received ≥1 dose of TCZ and had ≥1 post-dose efficacy assessment. Imputation with the last observation carried forward method was used in the event of missing data. The mean change in the DAS28-ESR from week 24 to week 40 in each treatment arm and the overall difference in the mean change between treatment arms were estimated based on analysis of covariance, adjusted for stratification factors used in randomization (baseline [week 0] weight-by-dosing group [<80 kg every 2 weeks; <80 kg weekly; 80 to <100 kg every 2 weeks; 80 to <100 kg weekly; ≥100 kg weekly], TNF inhibitor exposure [yes/no], and the week 24 DAS28-ESR [<2.6; ≥2.6 to ≤3.2]). To claim noninferiority, the upper bound of the 2-sided * Except where indicated otherwise, values are the mean AE SD. TCZ = tocilizumab; MTX = methotrexate; RA = rheumatoid arthritis; RF = rheumatoid factor; ACPA = anti-citrullinated protein antibody; BMI = body mass index; DMARDs = disease-modifying antirheumatic drugs; TNF = tumor necrosis factor; DAS28-ESR = Disease Activity Score in 28 joints using the erythrocyte sedimentation rate; CDAI = Clinical Disease Activity Index; SDAI = Simplified Disease Activity Index; VAS = visual analog scale; HAQ = Health Assessment Questionnaire; CRP = C-reactive protein.
95% confidence interval (95% CI) for the difference in change in the DAS28-ESR (for the TCZ monotherapy group minus the change in the DAS28-ESR for the TCZ plus MTX group) was required to be <0.6. A noninferiority margin of 0.6 was defined based on the requirement for a ≥0.6-unit change in order to meet a change in the European League Against Rheumatism response criteria (26) , because changes of <0.6 were within the measurement error of the DAS methodology (27) . To assess the robustness of the primary end point, the analyses were repeated in the per-protocol population and the completer population, and a repeated-measures model was performed in the randomized population. For the secondary efficacy end points, a Cochran-MantelHaenszel test was used to assess the differences in rates for each treatment, adjusted for stratification factors used in randomization, including the percentage of patients with worsening in the DAS28-ESR of ≥1.2 and the percentage of patients achieving low disease activity (DAS28-ESR ≤3.2), remission (DAS28-ESR <2.6), and ACR20/50/70 responses at week 40 and week 52.
RESULTS

Patient disposition and baseline characteristics.
Of 718 patients enrolled, 296 achieved a DAS28-ESR of ≤3.2 at week 24 and were randomized to receive either TCZ monotherapy or TCZ plus MTX ( Figure 1B) . Two of the randomized patients were not treated after week 24; therefore, 294 randomized patients were included in the intent-to-treat population (for TCZ monotherapy, n = 147; for TCZ plus MTX, n = 147). Among the 294 randomized patients, 33 discontinued (for TCZ monotherapy, n = 18 [12.2%]; for TCZ plus MTX, n = 15 [10.2%]). Patient demographics and clinical characteristics at baseline (week 0) were balanced across the TCZ monotherapy and TCZ plus MTX groups ( Table 1 ). The mean RA duration, tender joint count, swollen joint count, and DAS28-ESR were comparable between the groups.
Efficacy. At week 24 (at the time of randomization, prior to MTX withdrawal), the DAS28-ESR was similar in both groups of randomized patients; the mean AE SD DAS28-ESR was 2.11 AE 0.82 for the TCZ monotherapy group and 2.13 AE 0.82 for the TCZ plus MTX group. The study met its primary end point by demonstrating the noninferiority of TCZ monotherapy compared with TCZ plus MTX. The change in the DAS28-ESR from baseline (week 0) to week 40 was similar between the randomized treatment groups (Figure 2) . The adjusted mean change in the DAS28-ESR from week 24 to week 40 was 0.46 (95% CI 0.22, 0.70) in the TCZ monotherapy group and 0.14 (95% CI À0.11, 0.39) in the TCZ plus MTX group for the randomized population. The adjusted difference between the groups was 0.318 (95% CI 0.045, 0.592), demonstrating the noninferiority of discontinuing MTX compared with continuing MTX in patients who had achieved low disease activity while receiving TCZ plus MTX. The sensitivity analyses supported the results of the primary efficacy end point. The estimated mean difference in the mean change in the DAS28-ESR from week 24 to week 40 was 0.311 (95% CI 0.024, 0.597) for the per-protocol population, 0.26 (95% CI À0.01, 0.54) for the completers population, and 0.29 (95% CI 0.02, 0.56) for the randomized population, using a repeated-measures model.
The proportions of patients with worsening in the DAS28-ESR of ≥1.2 between week 24 and week 40 and between week 24 and week 52 were similar between the treatment groups (42 patients [28.6%] Figure 3A and Table 2 ). The proportions of patients who maintained low disease activity or remission 
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based on the DAS28-ESR at weeks 40 and 52 were similar between the TCZ monotherapy and TCZ plus MTX groups, with the exception of low disease activity at week 40, which slightly favored the TCZ plus MTX group ( Figure 3B and Table 2 ). At week 40, 49.7% of patients in the TCZ monotherapy group (n = 73) and 59.2% of patients in the TCZ plus MTX group (n = 87) were in disease remission (between-group difference À9.5% [95% CI À20.9, 1.8]); at week 52, 48.3% of patients (n = 71) and 55.1% of patients (n = 81), respectively, were in disease remission (between-group difference À6.8% [95% CI À18.2, 4.6]). At week 40, low disease activity was maintained in 63.3% of patients (n = 93) in the TCZ monotherapy group compared with 76.9% of patients (n = 113) in the TCZ plus MTX group (between-group difference À13.6% [95% CI À24.0, À3.3]); at week 52, 62.6% of patients in the TCZ monotherapy group (n = 92) and 68.0% of patients in the TCZ plus MTX group (n = 100) had low disease activity (between-group difference À5.4% [95% CI À16.3, 5.4]) ( Figure 3B and Table 2 ). Mean Clinical Disease Activity Index (28) scores were similar between the TCZ monotherapy and TCZ plus MTX groups from week 24 (randomization) to week 52, consistent with the results observed for the DAS28-ESR ( Figure 3C ). Whereas DAS28-ESR scores were similar between the randomized groups at 24 weeks, there was an imbalance in the proportions of patients who achieved ACR20/ 50/70 responses from baseline (week 0) to week 24; the rates of response were~8-11% lower in the group that was ultimately randomized to receive TCZ monotherapy than in the group randomized to receive TCZ plus MTX at week 24. This trend did not change following MTX withdrawal ( Figure 3D ). Safety. The safety population included all treated patients with safety assessments after baseline (week 0). The rates of AEs and SAEs occurring from randomization until the end of the study were comparable between the TCZ monotherapy and TCZ plus MTX groups, although the frequency of AEs in the TCZ plus MTX group was higher than that in the TCZ monotherapy group (Table 3 ). The most common SAE was infection (≥1), which occurred in 2.1% of patients in the TCZ monotherapy group and 2.2% in the TCZ plus MTX group. Four deaths occurred in the study, none of which was judged by the investigator to be related to study treatment. No deaths occurred in the randomized cohort.
Elevation of alanine aminotransferase and aspartate aminotransferase levels of 3 times the upper limit of normal (ULN) was observed in 33 (4.7%) and 12 (1.7%) of the 713 patients in the safety population, respectively. In the randomized cohort, 2 patients in the TCZ plus MTX group and none in the TCZ monotherapy group had an elevation of transaminase levels of 3 times the ULN.
Of the 713 patients in the safety population, 686 (96.2%) had a valid screening assay for anti-TCZ antibodies at baseline (week 0) and at any time post-baseline. Of the 686 patients with baseline (week 0) and post-baseline screening assay results, 10 (1.5%) developed treatmentinduced anti-TCZ antibodies (all before week 24, while receiving TCZ plus MTX); of these, 9 patients (1.3%) developed neutralizing anti-TCZ antibodies while receiving TCZ plus MTX prior to week 24, but none were positive for the IgE isotype. No patients developed anti-TCZ antibodies after week 24. No patients experienced anaphylaxis or serious hypersensitivity. One patient (receiving TCZ plus MTX) with neutralizing antibodies withdrew from the study due to lack of efficacy.
DISCUSSION
The results of the current study demonstrate the statistical noninferiority of TCZ monotherapy compared with TCZ plus MTX in patients who achieve low disease activity with TCZ plus MTX and subsequently discontinue MTX. The mean change in the DAS28-ESR from week 24 to week 40 was similar between patients randomized to TCZ monotherapy and those randomized to TCZ plus MTX. Except for the proportion of patients with low disease activity (DAS28-ESR <3.2) at week 40, secondary efficacy analyses supported the noninferiority of TCZ monotherapy compared with TCZ plus MTX. Across different end points and time points, there was an overall trend toward slightly higher responses in patients who continued MTX therapy; however, these differences were not clinically meaningful. A general trend toward slightly lower rates of ACR 20/50/70 responses at week 40 and week 52 was observed in the TCZ monotherapy group compared with the TCZ plus MTX group; however, these rates were already slightly imbalanced at randomization (week 24), with lower response rates observed in the patients randomized to the TCZ monotherapy group compared with patients randomized to the TCZ plus MTX group, making it difficult to attribute any observed differences in ACR responses between groups at week 40 and week 52 to the treatment effect. This is the first controlled study to examine discontinuation of MTX in patients receiving TCZ and is among the first to demonstrate efficacy of the subcutaneous formulation of TCZ as monotherapy. The results are consistent with those of previous studies demonstrating the efficacy of subcutaneous TCZ (8, 9) and with other studies comparing intravenous TCZ monotherapy with TCZ plus MTX (14, 15) . The ACT-RAY trial also evaluated the efficacy of TCZ with or without MTX in a patient population similar to that in the current study but did not evaluate MTX withdrawal following response to TCZ plus MTX. At baseline, patients with an inadequate response to MTX either switched from their current MTX dose to intravenous TCZ monotherapy or continued to receive MTX but added intravenous TCZ (TCZ plus MTX) throughout the duration of the study. At 24 weeks and 52 weeks, similar proportions of patients in the TCZ monotherapy and TCZ plus MTX groups achieved remission as defined by the DAS28-ESR (14, 15) .
MTX coadministration has been associated with increased efficacy of TNF inhibitors. Studies evaluating the impact of various doses of MTX in patients treated with a TNF inhibitor, such as adalimumab or golimumab, showed decreased therapeutic benefit when TNF inhibitors were used in combination with decreased doses of MTX (29, 30) . Additionally, the Canadian Methotrexate and Etanercept Outcome study failed to demonstrate noninferiority of switching to placebo versus continuing MTX in patients achieving low disease activity while receiving etanercept plus MTX (31) . These results do not support the clinical utility of dose reduction or discontinuation of MTX in patients receiving a TNF inhibitor.
One potential mechanism for the additive benefit of MTX in combination with a TNF inhibitor is the impact of MTX on inhibition of anti-drug antibody formation against TNF inhibitors, thereby impacting serum levels of TNF inhibitors and resulting in increased efficacy (29, 30, (32) (33) (34) . Conversely, a recent study of pooled clinical trial data demonstrated that the risk of developing anti-drug antibodies with TCZ was low, regardless of whether TCZ was administered in combination with MTX or as monotherapy (35) . Although these studies did not directly assess the effect of MTX discontinuation during biologic treatment, the results suggest that the effect of MTX on the efficacy of biologics differs between biologics with different mechanisms of action. Furthermore, the apparent lack of additive efficacy of MTX combined with TCZ may be attributable to a potential overlap in the mechanisms of action between MTX and TCZ, because MTX itself has been shown to reduce serum levels of IL-6 in patients with RA (36) . Therefore, discontinuation of MTX in patients receiving TCZ may have less of an impact on efficacy than discontinuation of MTX in patients receiving a biologic with a different mechanism of action, particularly a TNF inhibitor.
Safety outcomes in this study were mostly similar between the randomized treatment arms; however, there was a slightly higher incidence of AEs in patients randomized to receive TCZ plus MTX than in those randomized to receive TCZ monotherapy (308.1 [95% CI 273.0, 346.0] versus 238.0 [95% CI 207.6, 271.6] per 100 patient-years). The safety profile was consistent with the known profile of TCZ, and no new safety signals were identified. The risk of immunogenicity observed in this study was low and consistent with that observed in previous studies of TCZ (35) .
The 40-week time point (16 weeks after the discontinuation of MTX in the TCZ monotherapy group) was selected for the primary outcome based on prior studies of MTX tapering and discontinuation that support the notion that 16 weeks is an adequate time frame for assessing the effects of MTX withdrawal. In a small double-blind study of RA patients receiving long-term MTX, all patients who were randomized to discontinue MTX experienced a disease flare after 1 month (37) . In another study, 30% of patients who switched from MTX weekly to every other week experienced a disease flare within 12 weeks of dose reduction (38) . In addition, the evaluation of MTX discontinuation after 16 weeks (week 24 to week 40) is consistent with real-world clinical practice, where patients receiving a biologic are evaluated (and treatment decisions are made) 4 months after changing the therapeutic regimen, such as discontinuation of MTX. Furthermore, the results observed at 40 weeks in this study are consistent with those observed at 52 weeks (7 months after MTX discontinuation), suggesting that 16 weeks was a sufficient length of time to observe the effects of MTX discontinuation.
Although discontinuation of a conventional synthetic DMARD in patients receiving biologic therapy for RA is a well-recognized practice, and approximately onethird of patients receive biologics as monotherapy (39, 40) , controlled studies examining the effect of discontinuing a conventional synthetic DMARD during biologic therapy are lacking. Overall, the results of the current study demonstrate that patients receiving TCZ plus MTX who achieve low disease activity can discontinue MTX while maintaining disease control during the 16 weeks following MTX discontinuation. The noninferiority of TCZ monotherapy compared with TCZ plus MTX observed in this study suggests that patients with RA receiving TCZ who cannot tolerate or prefer not to use MTX can safely discontinue it without significant worsening of disease activity.
